Q-omics provides the consensus-scored PLXNB3 profile across patient tissues and cancer cell-line models. PLXNB3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PLXNB3 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, PLXNB3 RNA expression shows 18,951 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LUAD, and UVM as cancer lineages where PLXNB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLXNB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLXNB3 survival associations across molecular data types. PLXNB3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (13) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLXNB3 RNA expression–survival associations across cancer types. High PLXNB3 expression shows unfavorable associations in KIRC, KIRP, BRCA, COAD, MESO and READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PLXNB3 RNA expression.
This table summarizes PLXNB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PLXNB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLXNB3 shows lower tumor expression in COAD and KICH and higher tumor expression in LUAD, HNSC, KIRC and LUSC. The LUAD box plot shows higher PLXNB3 RNA expression in tumor versus normal tissue (log2 FC = +2.142, t-test p < 0.001).
This table shows molecular features associated with PLXNB3 in patient tissues and cancer cell lines. In patient samples, PLXNB3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLXNB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and SKIN.
